These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 6481115)

  • 21. Comparison of results of long-term treatment of chronic hepatic encephalopathy with lactulose and sorbitol.
    Rodgers JB; Kiley JE; Balint JA
    Am J Gastroenterol; 1973 Nov; 60(5):459-65. PubMed ID: 4587191
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy.
    Watanabe A; Sakai T; Sato S; Imai F; Ohto M; Arakawa Y; Toda G; Kobayashi K; Muto Y; Tsujii T; Kawasaki H; Okita K; Tanikawa K; Fujiyama S; Shimada S
    Hepatology; 1997 Dec; 26(6):1410-4. PubMed ID: 9397979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients.
    Bajaj JS; Sanyal AJ; Bell D; Gilles H; Heuman DM
    Aliment Pharmacol Ther; 2010 May; 31(9):1012-7. PubMed ID: 20136802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study.
    Morgan MY; Alonso M; Stanger LC
    J Hepatol; 1989 Mar; 8(2):208-17. PubMed ID: 2654285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A clinical comparative study of crystalline pure lactulose and powder pure lactitol in portasystemic encephalopathy of cirrhotic patients].
    Grandi M; Sacchetti C; Pederzoli S; Celani MF
    Minerva Gastroenterol Dietol; 1991; 37(4):225-30. PubMed ID: 1805974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis.
    Sharma P; Sharma BC; Sarin SK
    Liver Int; 2009 Oct; 29(9):1365-71. PubMed ID: 19555401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study.
    Loguercio C; Del Vecchio Blanco C; Coltorti M
    J Int Med Res; 1987; 15(6):335-43. PubMed ID: 3125077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Plasma amino acids in patients with liver cirrhosis treated with lactulose].
    Giardina MG; Matarazzo M; Prantera T; Verre C; De Marco F
    Boll Soc Ital Biol Sper; 1984 Dec; 60(12):2309-16. PubMed ID: 6529509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathy.
    Heredia D; Terés J; Orteu N; Rodés J
    J Hepatol; 1988 Aug; 7(1):106-10. PubMed ID: 3053887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatic Encephalopathy.
    Blei AT; Córdoba J;
    Am J Gastroenterol; 2001 Jul; 96(7):1968-76. PubMed ID: 11467622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparative study of lactulose and neomycin in the treatment of porto-systemic encephalopathy].
    Sala Felis T; Berenguer J; Barrios JM; Gómez J
    Rev Esp Enferm Apar Dig; 1974 Feb; 42(3):335-42. PubMed ID: 4829021
    [No Abstract]   [Full Text] [Related]  

  • 32. Crystalline lactulose in the therapy of hepatic cirrhosis. Evaluation of clinical and immunological parameters. Preliminary results.
    Vendemiale G; Palasciano G; Cirelli F; Altamura M; De Vincentiis A; Altomare E
    Arzneimittelforschung; 1992 Jul; 42(7):969-72. PubMed ID: 1418064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isokinetic muscle strength and its association with neuropsychological capacity in cirrhotic alcoholics.
    Tarter RE; Panzak G; Switala J; Lu S; Simkevitz H; Van Thiel D
    Alcohol Clin Exp Res; 1997 Apr; 21(2):191-6. PubMed ID: 9113251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychomotor dysfunctions in alcoholic and post-necrotic cirrhotic patients without overt encephalopathy.
    Puca FM; Antonaci F; Panella C; Guglielmi FW; Barone M; Francavilla A; Cerutti R
    Acta Neurol Scand; 1989 Apr; 79(4):280-7. PubMed ID: 2728850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of latent portasystemic encephalopathy in an unselected population of patients with liver cirrhosis in general practice.
    Schomerus H; Schreiegg J
    Z Gastroenterol; 1993 Apr; 31(4):231-4. PubMed ID: 8493802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Helicobacter pylori infection, plasma ammonia levels, and psychometric testing in cirrhotic patients.
    Zullo A; Rinaldi V; Meddi P; Hassan C; Winn S; Attili AF
    Am J Gastroenterol; 1999 Aug; 94(8):2214-8. PubMed ID: 10445552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Control of endotoxinemia in liver disease by lactulose and paromomycin.
    Scevola D; Magliulo E; Trpin L; Benzi-Cipelli R; Bernardi R
    Boll Ist Sieroter Milan; 1979 Jul; 58(3):242-7. PubMed ID: 518757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Lactulose in treatment of hepatic encephalopathy in patient with liver cirrhosis].
    Shuliat'ev IS; Il'chenko LIu; Vinnitskaia EV; Petrakov AV; Sil'verstrova SIu
    Eksp Klin Gastroenterol; 2002; (5):38-41, 127. PubMed ID: 12619575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gastrointestinal transit in cirrhotic patients: effect of hepatic encephalopathy and its treatment.
    Van Thiel DH; Fagiuoli S; Wright HI; Chien MC; Gavaler JS
    Hepatology; 1994 Jan; 19(1):67-71. PubMed ID: 8276369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Portal systemic encephalopathy--should lactulose and neomycin be used together.
    Martin AJ
    Br J Clin Pract; 1981 Sep; 35(9):323-4. PubMed ID: 7326185
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.